Lirum Therapeutics, Inc. (LRTX)

Lirum Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	0.49	0.49	0.12
Research & Development	1.7	1.7	1.78
Operating Expenses	2.19	2.19	1.91
Operating Income	-2.19	-2.19	-1.91
Interest Expense / Income	0.01	0.01	0.01
Other Expense / Income	-4.4	-4.4	-3.84
Pretax Income	2.2	2.2	1.92
Net Income	2.2	2.2	1.92
Net Income Growth	-	14.70%	-
Free Cash Flow	-2.24	-2.24	-0.31
EBITDA	2.21	2.21	1.93
EBIT	2.21	2.21	1.93

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).